2-CdA
2-CdA Brand names, 2-CdA Analogs
2-CdA Brand Names Mixture
- No information avaliable
2-CdA Chemical_Formula
C10H12ClN5O3
2-CdA RX_link
http://www.rxlist.com/cgi/generic3/cladribine.htm
2-CdA fda sheet
2-CdA msds (material safety sheet)
2-CdA Synthesis Reference
No information avaliable
2-CdA Molecular Weight
285.687 g/mol
2-CdA Melting Point
215 oC
2-CdA H2O Solubility
No information avaliable
2-CdA State
Solid
2-CdA LogP
1.57
2-CdA Dosage Forms
Solution
2-CdA Indication
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.
2-CdA Pharmacology
Cladribine is a synthetic antineoplastic agent with immunosuppressive effects. Cladribine is one of a group of chemotherapy drugs known as the anti-metabolites. Anti-metabolites stop cells making and repairing DNA. Cancer cells need to make and repair DNA in order to grow and multiply.
2-CdA Absorption
Oral bioavailability is 34 to 48%.
2-CdA side effects and Toxicity
Symptoms of overdose include irreversible neurologic toxicity (paraparesis/quadriparesis), acute nephrotoxicity, and severe bone marrow suppression resulting in neutropenia, anemia and thrombocytopenia.
2-CdA Patient Information
LEUSTATIN (cladribine) Injection should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Suppression of bone marrow function should be anticipated. This is usually reversible and appears to be dose dependent. Serious neurological toxicity (including irreversible paraparesis and quadraparesis) has been reported in patients who received LEUSTATIN Injection by continuous infusion at high doses (4 to 9 times the recommended dose for Hairy Cell Leukemia). Neurologic toxicity appears to demonstrate a dose relationship; however, severe neurological toxicity has been reported rarely following treatment with standard cladribine dosing regimens. Acute nephrotoxicity has been observed with high doses of LEUSTATIN (4 to 9 times the recommended dose for Hairy Cell Leukemia), especially when given concomitantly with other nephrotoxic agents/ therapies.
2-CdA Organisms Affected
Humans and other mammals
